MBRX Stock Discussion
Moleculin Biotech, Inc. Description
Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
Industry: Biotechnology
Keywords: Medicine Cancer Pharmaceutical Oncology Acute Myeloid Leukemia Chemotherapy Antineoplastic Drugs Blastoma Glioblastoma Stage Pharmaceutical Transcription Transcription Factors Refractory Acute Myeloid Leukemia Transcription Factor Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Popular Now
Featured Articles